

PCR-/NAT *Salmonella enterica* (RV 537) Nov 2025



Tabelle 1: Probenzusammensetzung und erwartetes Ergebnis.

Sample composition and expected results.

Proben Nr.	Erwartet / expected		Probenzusammensetzung / Sample composition
537A 251014 01	++	61	<i>S. enterica</i> ser. enteritidis (~ 5x10 ⁴ CFU/mL)
537A 251014 02	Ø	62	<i>Escherichia coli</i> K12
537A 251014 03	++	61	<i>S. enterica</i> ser. paratyphi (~ 5x10 ⁴ CFU/mL)
537A 251014 04	++	61	<i>S. enterica</i> ser. enteritidis (~ 1x10 ⁴ CFU/mL)

Tabelle 2: Häufigkeit der Mitteilung verschiedener Befunde.

Absolute numbers of reported individual results.

<i>n</i> = 29		Proben Nr. (Sample no.)				Inhibition				
Befund Result		01	02	03	04		01	02	03	04
Positiv		29	0	29	25	n.d.	0	0	0	0
Negativ		0	29	0	4	nein no	29	29	29	29
Fraglich Questionable		0	0	0	0	ja yes	0	0	0	0

Tabelle 3: Häufigkeit richtig positiver und richtig negativer NAT-Befunde bei Anwendern verschiedener Methoden.

Absolute numbers and relative frequency of reported true positive and true negative results among various NAT methods.

NAT-Methode [Code] (total number)	NAT richtig positiv True positive results						NAT richtig negativ	
	01		03		04		02	
	Absolut Absolute	%	Absolut Absolute	%	Absolut Absolute	%	Absolut Absolute	%
Amplex eazypex TyphiTyper (n= 1)	1	100	1	100	1	100	1	100
BD MAX Enteric Bacterial Panel (n= 5)	5	100	5	100	5	100	5	100
BioFire FILMARRAY GI Panel (n= 1)	1	100	1	100	1	100	1	100
Roche UC-TIB-Gastro-BAC (n= 2)	2	100	2	100	2	100	2	100
Seegene Allplex GI-Bacteria (I) (n= 6)	6	100	6	100	4	67	6	100
Seegene Allplex GI-EB Screening (n= 6)	6	100	6	100	4	67	6	100
TIB Molbiol LightMix Salmonella (n= 1)	1	100	1	100	1	100	1	100
RIDAGENE Bacterial Stool Panel (n= 2)	2	100	2	100	2	100	2	100
In house PCR assay (n= 3)	3	100	3	100	3	100	3	100
Other commercial tests (n= 2)	2	100	2	100	2	100	2	100

Comments:

1. The following tests are listed under "Other commercial tests": MIKROGEN ampliCube gastrointestinal Bacterial Panel 1 (1x) and QIAGEN QIAstat-Dx Gastrointestinal Panel (1x).